Asia Pacific Infectious Disease Diagnostics Market

The Asia Pacific infectious disease diagnostics market was valued at US$ 4,673.02 million in 2022 and is expected to reach US$ 8,165.77 million by 2030; it is estimated to grow at a CAGR of 7.2% from 2022 to 2030.

•    In August 2023, Danaher Corp entered into a definitive agreement to acquire Abcam plc. Danaher would acquire all of the outstanding shares of Abcam for US$ 24.00 per share in cash, or a total enterprise valued of approximately US$ 5.7 billion including assumed indebtedness and net of acquired cash.
  
  
•    In May 2021, Torus Biosystems launched the US$ 25 million program to advance infectious disease diagnostics across healthcare facilities.
  
  
•    In December 2021, Roche launched the first infectious illness tests on the Cobas 5800 System, a new molecular laboratory instrument. Cobas HIV-1/HIV-2 Qualitative, Cobas HBV, cobas HCV, cobas HIV-1, and Cobas Omni Utility Channel kit are a few of these options.
  
  
•    In June 2021, Bio-Rad Laboratories launched PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit, an accurate, sensitive, and cost-effective tool used to detect SARS-CoV-2 in a community's wastewater.
  
  
•    In April 2020, CerTest Biotec and B.D. (Becton, Dickinson, and Company) announced that VIASURE SARS-CoV-2 Real-Time PCR Detection Kit adapted for the BD MAX System has been CE marked to the IVD Directive (98/79/C.E.).
  
  The active participation of market participants in product innovation and development and an increase in product approvals are likely to boost the growth of the Asia Pacific infectious disease diagnostics market during 2022-2030.
  
  Asia Pacific Infectious Disease Diagnostics Market Overview
  
  According to a ChinaTown Online blog, in May 2022, ~1 in 7 people from the age range of 15-49 is infected with sexually transmitted diseases (STDs) in China. Chlamydia, gonorrhea, genital warts, and syphilis are the most common STDs. According to the WHO, overall ~370 million new cases of trichomoniasis, Neisseria gonorrhea (NG) infection, Chlamydia trachomatis (CT) infection, and syphilis, among others, were detected in China in 2020. ~35% of the new infections registered were CT, which is one of the world's most commonly reported sexually transmitted infections (STIs). Further, the rising number of public-public and public-private partnerships to address challenges posed by infectious disease burden in the country is expected to boost the market growth in the coming years. For Instance, the Centers for Disease Control and Prevention (CDC, US) has been in collaboration with the Government of China, along with other partners based in the country, for ~30 years, addressing public health priorities that affect the US, China, and the world.
  
  Asia Pacific Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Million)
  
  Asia Pacific Infectious Disease Diagnostics Market Segmentation
  
  The Asia Pacific infectious disease diagnostics market is segmented based on product, technology, application type, testing type, end user, and country.
  
  Based on product, the Asia Pacific infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held the largest share in 2022.
  
  By technology, the Asia Pacific infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The immunodiagnostics segment held the largest share in 2022. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.
  
  By application type, the Asia Pacific infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held a larger share in 2022.
  
  By testing type, the Asia Pacific infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held a larger share in 2022. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.
  
  By end user, the Asia Pacific infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held the largest share in 2022.
  
  Based on country, the Asia Pacific infectious disease diagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific infectious disease diagnostics market in 2022.
  
  Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, AccuBioTech Co Ltd, ACON Laboratories Inc, and DiaSorin SpA are some of the leading companies operating in the Asia Pacific infectious disease diagnostics market.